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Follicle-stimulating hormone (FSH), a major regulator of spermatogenesis, has a crucial
function in the development and function of the testis and it is extensively given as a
fertility treatment to stimulate spermatogenesis. We analyzed the effects of different FSH
preparations (α-follitropin, β-follitropin, and urofollitropin) in combination with testosterone
on porcine pre-pubertal Sertoli cells. To study the effect of the different FSH treatments
in the Sertoli cell function we performed Real Time PCR analysis of AMH, inhibin B,
and FSH-r, an ELISA assay for AMH and inhibin B, and a high-throughput comparative
proteomic analysis. We verified that all three preparations induced a reduction of AMH
in terms of mRNA and secreted proteins, and an increase of inhibin B in terms of mRNA
in all the FSH formulations, while solely α-follitropin produced an increase of secreted
inhibin B in the culture medium. Comparative proteomic analysis of the three FSH
preparations identified 46 proteins, 11 up-regulated and 2 down-regulated. Surprisingly,
the combination of testosterone with β-follitropin specifically induced an up-regulation
of eight specific secreted proteins. Our study, showing that the three different FSH
preparations induce different effects, could offer the opportunity to shed light inside new
applications to a personalized reproductive medicine.
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INTRODUCTION
Follicle-stimulating hormone (FSH), a glycoprotein hormone
secreted by the anterior pituitary gland, plays a key function in
the treatment of human infertility. In infertile women it is widely
prescribed to stimulate follicular development, meanwhile,
in males, it is used alone or in association with Human
chorionic gonadotropin (hCG) to trigger off and maintain
spermatogenesis both in hypogonadotropic hypogonadism (1),
and in oligozoospermic subjects with normogonadotropic
hypogonadism (2).
FSH comprises two subunits, α and β, which are both
glycosylated and contain four N-linked carbohydrates. The
different content in sialic acid at the C-terminal determines a
family of glycoforms that explain the structural and functional
heterogeneity of the different FSH formulations (3).
The preparations of FSH available in the market are derived
by either recombinant DNA technology (rFSH such as α- and β-
follitropin) or post-menopausal urines (urofollitropin). α- and β-
follitropins are synthesized by the same recombinant technology,
producing identical dimeric α-FSH and β-FSH subunits, but with
differences in the further glycosylation and in the procedures of
purification. In contrast, urofollitropin consists of FSH with a
minimal LH activity, and it has low specific activity (∼100–150
IU FSH/mg protein). The low specific activity of this preparation
could be explained by the fact that more than 95% of the
protein content correspond to non-specific co-purified urinary
proteins (1).
Regarding the efficacy of the different FSH preparations in the
female, many contradictory results have been published in the
last 2 decades. The meta-analyses regarding the clinical efficacy
of different FSH preparations demonstrated no significant
differences in clinical or ongoing pregnancy and in the live-birth
rate, in the miscarriage rate, or for the incidence of multiple
pregnancy rate or ovarian hyperstimulation syndrome (OHSS)
between rFSH and urofollitropin (4–8).
Up to now, in the male, no data exist regarding the efficacy
of the treatment in relation to the FSH-therapy used. However,
a meta-analysis reported a significant positive effect of the
treatment with FSH both on sperm parameters and on pregnancy
rate in oligozoospermic patients with normal FSH levels (9).
Unfortunately, the studies included in the meta-analyses have an
extremely heterogeneity in the selection criteria of the patients, in
primary and secondary end-points, in the doses of FSH treatment
and in time of treatment (10).
Sertoli cell (SC) is one of the principal actors in
spermatogenesis as it provides nourishment, and structural
and functional support to germ cells. Moreover, it protects germ
cells by the blood-testis barrier (BTB) and by the production
of immunomodulatory factors (11). In testis, FSH controls the
function of SC through FSH receptors (FSH-r), which are only
present in SC. In particular, FSH plays a pivotal role in the early
stages of spermatogenesis, while testosterone has a major role in
spermiogenesis (12).
In the prepubertal testis, SC is the most representative cell
population. However, during this stage, there is a low activity
of the hypothalamic–pituitary–gonadal axis reflected by the high
levels of Anti-Müllerian Hormone (AMH) and inhibin B in
serum (13). In contrast, during puberty, testosterone induces SC
maturation and inhibits AMH production (13).
The aim of this research was to assess the effects of the
different FSH formulation in an “in vitro” model of porcine
pre-pubertal SC, in order to evaluate the SC responsiveness to
pharmacological treatment of different FSH preparations, never
assessed until now.
MATERIALS AND METHODS
SC Culture, Characterization, and
Stimulation
Pure porcine pre-pubertal SC were isolated and characterized
according to previously reported methods (14–16).
Purified SC cultures, as previously stated (14–16), were treated
for 48 h as follows, and stimulation was performed according to
the previously described protocol (17):
• Stimulated with testosterone (0.2µg/ml; SIT, Pavia, Italy)
(control group);
• Stimulated with α-follitropin (α-FSH) 100 nM and
testosterone (0.2µg/ml);
• Stimulated with β-follitropin (β-FSH) 100 nM and
testosterone (0.2µg/ml);
• Stimulated with Urofollitropin (u-FSH) 100 nM and
testosterone (0.2µg/ml).
We used testosterone in addition to any of the FSH formulation
to mimic a physiological condition in testis, considering that
both FSH and testosterone are essential for the adequate
spermatogenesis (12).
Quantitative, Real-Time PCR
Analyses for AMH, inhibin B, and FSH receptor (FSH-r) were
performed as previously described (17) employing the primers
listed in Table 1. Total RNA was extracted from SC monolayers
obtained in the experimental groups using Trizol reagent (Sigma-
Aldrich, Milan, Italy), and quantified by reading the optical
density at 260 nm. In detail, 2.5 µg of total RNA was subjected
to reverse transcription (RT, Thermo Scientific, Waltham, MA,
USA) to a final volume of 20 µl. We performed the qPCR with
the use of 25 ng of the cDNA obtained by RT and a SYBR Green
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Master Mix (Stratagene, Amsterdam, The Netherlands). This
procedure was performed in an Mx3000P cycler (Stratagene),
using FAM for detection and ROX as the reference dye. We
normalized the mRNA level of each sample against β-actin
mRNA and expressed it as fold changes vs. the levels in the
control group.
Culture Media Isolation
Aliquots of the culture media (CM) of SC were collected after
48 h of stimulation, centrifuged at 1,500 g for 10min, and the
supernatant was saved at −20◦C for proteomic analysis and for
an ELISA assay for Inhibin B and AMH secretion performed as
previously described (18).
Proteomic Analysis of the SC Secretome
The SC CM for each sample was thawed and centrifuged at
3,000 g for 20min at 4◦C. The resulting supernatants were
filtered (0.45µm pore size) to remove cell debris and other
impurities if any. Afterward, to perform protein solubilization,
sodium dodecyl sulfate (SDS) and phenylmethylsulfonyl fluoride
(PMSF) were added to a final concentration of 2% (w/v) and
1mM, respectively. After 30min, all samples were centrifuged
at 4◦C at 16,000 g for 10min, and the supernatants (soluble
proteins) were kept, and proteins were precipitated overnight
in 80% cold acetone (v/v) at −20◦C. After centrifugation
at 17,530 g for 15min at 4◦C, the protein precipitates were
collected and resuspended in 1% SDS, 1mMPMSF in phosphate-
buffered saline (PBS) to perform protein quantification using
the BCA protein Assay Kit (PierceTM BCA protein Assay
Kit, Thermo Fisher Scientific, Rockford, IL), according to
manufacturer’s recommendations.
The TMT labeling was performed as described previously
(19, 20) and according to the manufacturer’s instructions.
Briefly, 50 µg of proteins from each sample were transferred
to a new tube and adjusted to a final volume of 50 µl
with 100mM triethylammonium bicarbonate (TEAB) to obtain
a 1 µg/µl concentration. Proteins were reduced in 9.5mM
tris (2-carboxyethyl) phosphine (TCEP), alkylated with 17mM
iodoacetamide (IAA), and precipitated by adding six volumes of
100% cold acetone. Then, samples were centrifuged at 17,500 g,
and the acetone-precipitated protein pellets (containing 50 µg
of proteins) were resuspended in 50 µl of 100mM TEAB.
Trypsin was added at a 1:22 protease-to-protein ratio and
incubated overnight at 37◦C. Prior to peptide labeling, an aliquot
from each sample was taken and combined at equal amounts
to form the internal control. After, 35 µg of peptides from
each sample (including the internal control) were labeled with
TMT isobaric tags (TMT 10-plex Mass Tag Labeling; Thermo
Fisher Scientific, Rockford, IL). The technical reproducibility and
analytical reliability of the approach were assessed by performing
duplicate analyses on the internal control. Then, 15 µl of
the TMT label reagents, previously resuspended in acetonitrile
anhydrous (ACN), were added to the corresponding sample,
followed by 1 h incubation at RT. Afterward, the reaction was
stopped by adding 5% hydroxylamine. The TMT-labeled samples
were combined at equal amounts constituting one multiplex
pool, which was dried in a vacuum centrifuge and resuspended
in 50 µl of 0.5% trifluoroacetic acid in 5% ACN. After, labeled
peptides were cleaned up via reversed-phase C18 spin columns
(Pierce C18 Spin Columns, Thermo Fisher Scientific, Rockford,
IL), according to manufacturer’s instructions. Then, the peptides
were reconstituted in 0.1% formic acid (FA) to be processed
by LC-MS/MS.
Our MS data was collected using a nano-LC Ultra 2D
Eksigent (AB Sciex, Brugg, Switzerland) attached to an LTQ-
Orbitrap Velos (Thermo scientific, San Jose, CA). Peptides were
injected onto a C18 trap column (L 2 cm, 100µm ID, 5µm,
120 Å; NanoSeparations, Nieuwkoop, the Netherlands) and
chromatographic analyses were performed using an analytical
column (L 15 cm, 75µm ID, 3µm, 100 Å; Thermo scientific,
San Jose, CA). The buffers used for the analysis were buffer
A (97% H2O-3% ACN, 0.1% FA) and buffer B (3% H2O-97%
ACN, 0.1% FA). A peptide mixture was loaded onto the analytical
column with the following gradient: time 0–5min, 0% of B;
5–180min, 0–32.5% of B; 180–185min, 32.5–100% of B at a
flow rate of 400 ml/min; and 185–200min, 100% of B at a
flow rate of 400 nl/min to avoid carry-over. MS/MS analyses
were performed using an LTQ-Orbitrap Velos (Thermo Fisher
Scientific, Waltham, MA) with a nanoelectrospray ion source.
The LTQ-Orbitrap Velos settings included one 30,000 resolution
at 400 m/z MS1 scan for precursor ions followed by MS2 scans
of the 15 most intense precursor ions, at 30,000 resolution
at 400 m/z, in positive ion mode. The lock mass option was
enabled, and mass calibration was performed on polysiloxane
(m/z 445.12003). MS/MS data acquisition was completed using
Xcalibur 2.1 (Thermo Fisher Scientific, Waltham, MA). MS2
experiments were performed using higher-energy collision
dissociation (HCD) with a normalized collision energy of 42%.
LC-MS/MS data was analyzed using Proteome Discoverer
1.4.1.14 (Thermo Fisher Scientific, Waltham, MA, USA) based
on SEQUEST HT cluster as search engine (University of
Washington, licensed to Thermo Electron Corp., San Jose, CA)
against UniProtKB/Swiss-Prot database with Sus scrofa (released
September 2018; 3,339 sequences). Searches were run applying
the following parameters: two maximum missed cleavage sites
for trypsin, TMT-labeled lysine (+229.163 Da) and methionine
oxidation (+15.995 Da) as dynamic modifications, cysteine
carbamidomethylation (+57.021 Da) as a static modification, 20
ppm precursor mass tolerance, 0.6 Da fragment mass tolerance.
Percolator was used for protein identification, applying the
following identification criteria: at least one unique peptide
per protein and a FDR of 1%. The reporter ion intensities
were corrected according to the isotopic purities provided by
the manufacturer.
For protein quantification purposes, only unique peptides
were used, and protein ratios (i.e., TMT-127/TMT-126) were
normalized to protein median. The cut-off for up-regulated
proteins was ≥1.500, and for down-regulated proteins was ≤
0.667 as previously reported (21).
Statistical Analysis
Values reported in the figures are the mean ± S.D. of three
independent experiments, each one performed in triplicate.
Statistical analysis was performed by the paired Student’s t-test
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using SigmaStat 4.0 software (Systat Software Inc., CA, USA). All
tests were performed in triplicate, and statistically significance
was assigned for p < 0.05.
RESULTS
Purification and Characterization of SC
The isolated SC culture was 95% pure as indicated by
immunostaining for AMH (Figure 1a) with an extremely
low percentage of non-SC cells (<5%) characterized by
immunostaining for insulin-like 3-positive (Leydig) cells (INSL-
3) (Figure 1b), alpha-smooth muscle actin positive (peritubular
myoid) cells (ASMA) (Figure 1c) and protein gene product
9.5-positive (gonocytes and spermatogonial) cells (PGP9.5)
(Figure 1d).
Inhibin B, AMH, and FSH-r Gene
Expression in SC
AMH gene expression in SC was significantly down-regulated
by treatment with α-, β-follitropin, and urofollitropin in
combination with testosterone treatment compared with
testosterone alone (Figure 2A, p < 0.001).
In contrast, inhibin B expression was significantly increased
after treatment with α-, β-follitropin, and urofollitropin, each
other combined with testosterone treatment compared with
testosterone alone (Figure 2A, p < 0.001).
Moreover, we found a statistically significant reduction
of FSH-r upon all three FSH preparations plus testosterone
compared with testosterone alone (Figure 2A, p < 0.001).
Inhibin B and AMH Secretion Assay
The secretion of AMH was significantly down-regulated by
α-, β-follitropin, and urofollitropin plus testosterone treatments
compared with testosterone alone, consistent with the results of
gene expression showed above (Figure 2B, p < 0.001).
Meanwhile, inhibin B was significantly increased in culture
medium only after exposure to α-follitropin plus testosterone
(Figure 2B, p < 0.001), while no changes were observed after
β-follitropin plus testosterone stimulation. Interestingly, we
observed a significant reduction of inhibin B after the stimulation
with urofollitropin plus testosterone compared with testosterone
alone (Figure 2B, p < 0.05).
Secretomic Protein Profiling
In order to evaluate the differences induced by the
different FSH preparations on SC secretomic profiles,
we performed a comparative proteomic analysis of the
SC culture media in the groups treated with testosterone
associated with α-, β-follitropin, and urofollitropin,
and we compared it with the group of the testosterone
treatment alone.
The proteomic analysis resulted in the identification of 46
TMT-labeled proteins in all the SC culture media proteomes
(Table 2). Of those, 13 proteins were detected in a significantly
altered abundance (Table 3). Specifically, 11 proteins were
observed as up-regulated (Table 3; cut-off ≥ 1.500) and 2
proteins as down-regulated (Table 3; cut-off ≤ 0.667) by the
different FSH preparations. All the different FSH preparations
showed a down-regulation of the secreted SPARC protein
FIGURE 1 | Sertoli cells characterization by immunofluorescence staining (green color). Sertoli cell monolayers were characterized by the expression of (a) AMH, (b)
INSL3, (c) ASMA, and (d) (PGP9.5). Nuclei are labeled with DAPI in blue color. Bars = 20µm.
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FIGURE 2 | Real-time PCR analysis and ELISA assays. (A) Gene expression in SC of AMH, inhibin B, and FSH-r. (B) AMH and inhibin B secretion in SC culture
medium. Data represent the mean ± S.D. (*p < 0.05, **p < 0.001) of three independent experiments performed in triplicate.
and an up-regulation of 3 proteins (PLAT, INHBA, and
TPI1, Table 3).
Interestingly, an up-regulation of 8 additional secreted
proteins (ACTB, UBC, PRDX2, PPIA, SPP1, HBB, MIF, and
S100A6) and a down-regulation of Histone H4 were specifically
observed after the use of β-FSH with T, as reported in Table 3.
DISCUSSION
In the present work, we have focused on the “in vitro” effect of
different FSH preparations on pre-pubertal porcine SC culture,
evaluating the modulation of specific markers determined
through different approaches. All the FSH preparations assessed
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TABLE 2 | List of the 46 TMT-labeled proteins identified in the Sertoli cell culture.
Accession Gene name Description Coverage # Proteins # Peptides # Unique Peptides MW (kDa)
P08835 ALB Serum albumin 14.00 1 12 12 69.6
Q29549 CLU Clusterin 40.36 1 14 14 51.7
P01025 C3 Complement C3 16.68 1 21 21 186.7
P04087 INHA Inhibin alpha chain 31.04 1 8 8 39.2
Q6QAQ1 ACTB Actin, cytoplasmic 1 22.40 1 6 2 41.7
P20305 GSN Gelsolin (Fragment) 11.79 1 7 7 84.7
Q9GKQ6 BGN Biglycan (Fragments) 31.99 1 7 7 30.4
P00761 N/A Trypsin 9.96 1 2 2 24.4
P18648 APOA1 Apolipoprotein A-I 32.83 1 7 7 30.3
P02543 VIM Vimentin 8.37 1 4 4 53.6
P04404 CHGA Chromogranin-A (Fragment) 16.59 1 5 5 49.3
P20112 SPARC SPARC 24.67 1 6 6 34.2
P68137 ACTA1 Actin, alpha skeletal muscle 15.65 1 5 1 42.0
P0CG68 UBC Polyubiquitin-C 32.83 2 2 2 60.0
Q29095 PTGDS Prostaglandin-H2 D-isomerase 16.40 1 3 3 20.6
Q8SQ23 PLAT Tissue-type plasminogen activator 8.54 1 3 3 63.6
Q1KYT0 ENO3 Beta-enolase 8.06 1 2 2 47.1
P80031 GSTP1 Glutathione S-transferase P 7.73 1 1 1 23.5
P35624 TIMP1 Metalloproteinase inhibitor 1 9.18 1 1 1 23.1
P62802 N/A Histone H4 11.65 1 1 1 11.4
A5A8V7 HSPA1L Heat shock 70 kDa protein 1-like 6.08 1 2 2 70.3
P10668 CFL1 Cofilin-1 18.67 2 2 2 18.5
Q9XSD9 DCN Decorin 5.28 1 2 2 39.9
Q49I35 LGALS1 Galectin-1 5.93 1 1 1 14.7
P52552 PRDX2 Peroxiredoxin-2 (Fragment) 7.09 1 1 1 14.2
O97763 NPC2 NPC intracellular cholesterol transporter 2 16.78 1 2 2 16.3
P79295 AMH Muellerian-inhibiting factor 7.65 1 3 3 61.5
P62936 PPIA Peptidyl-prolyl cis-trans isomerase A 5.49 1 1 1 17.9
Q29243 DAG1 Dystroglycan 1.82 1 1 1 95.4
P14287 SPP1 Osteopontin 5.28 1 1 1 33.6
P00690 AMY2 Pancreatic alpha-amylase 2.74 1 1 1 57.0
P43368 CAPN3 Calpain-3 1.83 1 1 1 94.5
P00172 CYB5A Cytochrome b5 6.72 1 1 1 15.3
P29412 EEF1B Elongation factor 1-beta 6.70 1 1 1 24.6
P02067 HBB Hemoglobin subunit beta 6.12 1 1 1 16.2
O02705 HSP90AA1 Heat shock protein HSP 90-alpha 1.91 1 1 1 84.7
P03970 INHBA Inhibin beta A chain 7.08 1 2 2 47.4
P01315 INS Insulin 19.44 1 1 1 11.7
P80928 MIF Macrophage migration inhibitory factor 7.83 1 1 1 12.4
Q2EN75 S100A6 Protein S100-A6 8.89 1 1 1 10.1
P03974 VCP Transitional endoplasmic reticulum ATPase 2.11 1 1 1 89.2
Q29371 TPI1 Triosephosphate isomerase 6.05 1 1 1 26.7
P42639 TPM1 Tropomyosin alpha-1 chain 4.58 1 1 1 32.7
P09571 TF Serotransferrin 2.01 1 1 1 76.9
P50390 TTR Transthyretin 4.67 1 1 1 16.1
P04185 PLAU Urokinase-type plasminogen activator 3.85 1 1 1 49.1
N/A, Not applicable.
in the current study, α-, β-follitropin, and urofollitropin, induced
a significant and similar response in terms of down-regulation of
both AMH gene expression and AMH secretion, up-regulation of
inhibin B gene expression and down-regulation of the expression
of FSH-r gene expression. AMH is a glycoprotein dimeric
hormone, a member of the transforming growth factor β (TGF-β)
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TABLE 3 | List of the up- and down-regulated proteins in Sertoli cell medium after stimulation with the different FSH preparations plus testosterone, compared with
testosterone treatment alone.
Accession Gene name Description αFSH+T/T βFSH+T/T uFSH+T/T
P03970 INHBA Inhibin beta A chain 1.804 1.835 3.084
Q8SQ23 PLAT Tissue-type plasminogen activator 1.881 2.533 1.857
Q29371 TPI1 Triosephosphate isomerase 1.786 2.132 1.562
Q6QAQ1 ACTB Actin, cytoplasmic 1 1.377 1.618 1.147
P0CG68 UBC Polyubiquitin-C 1.185 1.500 1.357
P52552 PRDX2 Peroxiredoxin-2 (Fragment) 1.459 1.634 1.077
P62936 PPIA Peptidyl-prolyl cis-trans isomerase A 1.358 1.980 1.076
P14287 SPP1 Osteopontin 1.016 2.134 1.191
P02067 HBB Hemoglobin subunit beta 1.270 1.814 1.336
P80928 MIF Macrophage migration inhibitory factor 1.412 1.513 1.233
Q2EN75 S100A6 Protein S100-A6 1.302 1.564 1.100
P20112 SPARC SPARC 0.589 0.474 0.485
P62802 N/A Histone H4 1.275 0.630 1.049
N/A, Not applicable.
The values in bold indicate the cut-off ≥1.500 for up-regulated proteins, and ≤ 0.667 for down-regulated proteins.
family, that plays a pivotal function in fetal sex differentiation,
being involved in the regression of the Müllerian ducts (22).
In the male, SC secretes high amounts of AMH from fetal life
until the onset of puberty. AMH is exclusively secreted by SC
and, for this reason, it is widely considered an important marker
of the testicular function during the pre-pubertal life (22). We
observed that testosterone alone and in combination with the
three FSH preparations induced a significant down-regulation
in AMH mRNA expression and secretion. As expected, we
also demonstrated a statistically significant reduction in FSH-r
expression independently of the FSH preparation. These data are
in accordance with literature reporting how the interaction of the
hormone with its receptor leads to the down-regulation of FSH-
r mRNA expression by a cAMP-dependent post-transcriptional
mechanism (23).
Another specific and important marker of SC functionality
is inhibin B, which provides for a negative feedback on FSH
secretion. In particular, serum inhibin B concentration is high
during early postnatal life, and then gradually is reduced to
a detectable plateau-level until its increase at the beginning
of puberty (12). The assay of inhibin B is used in clinical
practice to evaluate the presence and function of SC during
childhood. Additionally, in adult life, the inhibin B levels depend
on the presence of germ cells thus reflecting the efficiency of
spermatogenesis (24). Our results demonstrated that all three
FSH preparations plus testosterone significantly induced an up-
regulation in the levels of inhibin B mRNA, confirming the role
of FSH in inducing the transcription of inhibin B gene.
Our SC secretomic analysis uncovered a similar response
after stimulation of SC with the different FSH preparations.
On the one hand, we demonstrated the reduction levels of
secreted SPARC protein after stimulation of SC with the different
FSH preparations. SPARC, also known as osteonectin or BM-
40, is a multifunctional protein that can modulate cell shape,
proliferation, differentiation, and migration (25). SPARC has
been found to interact with structural matrix proteins and may
act to mediate their interactions with cells (24–28). In addition,
SPARC can regulate the activity of several signaling molecules,
either by direct interaction or by interfering with their signaling
pathways (29–31). In our scenario, it is known that SPARC
is produced by Leydig and Sertoli cells (32, 33), and that it
is internalized in Sertoli, Leydig, and germ cells (34), playing
a paracrine regulatory role during fetal testis development.
Furthermore, the expression of SPARC in SC bearing late-stage
elongate spermatids might suggest a role in the spermiation of
elongated spermatids (33). Future studies will comprehensively
define the function of SPARC in Sertoli-germ cell interaction and
spermiogenesis. Here we provide for the first time information
about the down-regulation of SPARC secretion by FSH.
On the other hand, the proteomic analysis also showed
that tissue-type plasminogen activator (PLAT), triosephosphate
isomerase (TPI1), and inhibin beta A chain (INHBA) proteins
were up-regulated by the stimulation with α-, β-follitropin,
and urofollitropin in presence of normal androgen milieu.
Specifically, the inhibin beta A chain was observed as upregulated
in proteomics by all the FSH preparations, and the higher
increase was observed for urofollitropin. Despite this evidence,
only α-follitropin stimulation induced a significative increase in
the inhibin B levels in the medium, as documented by ELISA.
INHBA is a subunit of both activin B and inhibin B (24). In the
testis, it has been postulated that activin B acts as an autocrine
and paracrine regulator of spermatogenesis (35, 36), modulating
the proliferation in the testis of germ cells and SC (37). We
might speculate that β-follitropin and, especially, urofollitropin,
induce the activation of the INHB gene and the production of
INHB, but do not increase the levels of INHB in the medium
since they might increase the levels of activin B instead of
inhibin B. Further studies are so needed to understand how
the different FSH preparations modify the inhibin B and activin
B balance.
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The remaining two up-regulated proteins have been
previously associated with SC. For example, previous studies
demonstrated low levels of PLAT activity in cultured SC under
basal conditions, whereas FSH stimulation induces PLAT
(38, 39). Our results through a quantitative in vitro secretomic
approach support the increased secretion of PLAT after FSH
treatment independently of the FSH preparation. Interestingly,
the plasminogen activator system acts in the process of
spermiation (40), the detachment of residual bodies from the
mature spermatids (41), and the residual body phagocytosis
by SC (42). Triosephosphate isomerase has moreover been
previously reported to be expressed in SC (43). An increased
TPI1 expression in SC may influence the early activities of
spermatogenesis, such as mitosis or initiation of meiosis, by
spermatogonia or pre-leptotene spermatocytes, respectively (43).
Surprisingly, the combination of β-follitropin with
testosterone revealed specific effects in the SC function
besides the aforementioned similar effect of all tested FSH
treatments. Specifically, the levels of eight additional proteins
were up-regulated, which were: Actin (ACTB), Polyubiquitin-C
(UBC), Peroxiredoxin-2 (PRDX2), Peptidyl-prolyl cis-trans
isomerase A (PPIA), Osteopontin (SPP1), Hemoglobin subunit
beta (HBB), Macrophage migration inhibitory factor (MIF), and
Protein S100-A6 (S100A6); and just one protein, Histone H4,
was down-regulated.
It is important to underline that some of these proteins might
have a pivotal role both in the germ cell migration and in the
cell-to-cell contact at the blood-testis barrier (BTB). For example,
actin filament bundles have been described in specific Sertoli cell
regions that are adjoining to tight junctions and to the sites of
adhesion to spermatogenic cells (44). During spermatogenesis,
these actin bundles undergo organizational changes, which
might play a role in changing the interrelationship between SC
and germ cells by facilitating the movement of spermatogenic
cells (44). Similarly, SPP1, synthesized by SC and germ cells,
is involved in cell adhesion and migration (45), and MIF,
produced by SC under basal conditions, induces the migration
of spermatogonial cells (46). Also, we found up-regulation of
PPIA, a protein highly expressed in SC that has been recognized
as a crucial factor in BTB integrity and maintenance (47), as
well as S100A6, a protein that promotes cell migration and
influences cell junction of SC (48) that could be implied in the
spermatogenesis and modulation of BTB.
Interestingly, β-follitropin also increased PRDX2, an
antioxidant protein preferentially expressed in SC that might
play a role in removing or regulating the intracellular levels
of peroxides produced during metabolism (49, 50). Additional
up-regulated proteins were HBB, a metalloprotein that acts as a
scavenger balancing the level of carbon monoxide (CO) in testis
(51), and UBC, which is required for normal spermatogenesis
development (52).
In conclusion, α-, β-follitropin, and urofollitropin induced a
similar response as expressed by the down-regulation of AMH
gene expression and AMH secretion, and an up-regulation
and down-regulation of inhibin B and FSH-r gene expression,
respectively, thus exerting an interesting effect in inducing
maturation of SC from a pre-pubertal to an adult phenotype.
This data confirms that the FSH in presence of an androgenic
milieu regulates the proliferation and functional maturation
of Sertoli cell type (53). Moreover, all three FSH preparations
induced a down-regulation of a spermiation related protein,
the SPARC, supporting the role of FSH in the regulation of
spermatogenesis. Nevertheless, there are some specific effects of
each FSH preparation, which need consideration before their
prescription to infertile males.
For instance, only α-follitropin, in association with
testosterone, induced the secretion in the media of inhibin
B. Since inhibin B secreted by Sertoli cells could serve as negative
feedback control on the hypothalamic-pituitary system to
decrease FSH release (54), we might suppose that α-follitropin
could have an inhibitory effect on the hypothalamic/pituitary
axis in vivo. If these preliminary data obtained in our in vitro
model would be confirmed by further in vitro and in vivo
studies, we might conclude that male secondary hypogonadism
would represent the best indication for this treatment since
it induces a good response in terms of Sertoli activation, and
the increase in Inhibin B secretion does not have any clinical
relevance. In contrast, the increase of Inhibin B secretion as a
response to α-follitropin treatment might represent a problem
for normogonadotropic infertile patients since it might inhibit
physiological pituitary FSH secretion.
In the case of urofollitropin, it induces a similar secretomic
profile but also an increase in the release of INHBA without
increasing the levels of secreted inhibin B, suggestive of
an increasing release of activin B. This panel of action
might be useful for treating oligozoospermic patients with
normal FSH secretion. Therefore, we might speculate that—
if these preliminary data would be confirmed—urofollitropin
might represent the best treatment option for patients with
normogonadotropic hypogonadism, since it seems to induce
an increase in the secreted proteins, including the A chain of
inhibin B and, consequentially, activin B, without increasing
the levels of inhibin B, which might interfere with pituitary
FSH secretion.
Finally, β-FSH stimulation exhibits additional effect up-
regulating specific proteins mainly related to spermatogenic cell
migration and BTB maintenance. In this context, the stimulation
of SC with β-follitropin exerts his effect in the modulation of
additional proteins implicated in the last stage of spermiation and
in the related antioxidant activity. Further studies are needed to
confirm that β-follitropin treatment is the best treatment option
for patients with a spermatogenic arrest at the spermatid stage, as
suggested by these preliminary in vitro data.
This molecular and proteomic approach demonstrated how
some molecular effects seem to have a specific signature
depending on each FSH preparation. The different molecular
responses could help to choose which of the different FSH
preparations could be used for infertility treatment according
to the different present physio-pathological conditions. We
can argue that α-follitropin can find a specific clinical use
in hypospermatogenesis due to hypogonadotropic stimulus or
in inducing spermatogenesis in puberty; β-follitropin could be
specifically indicated to improve spermiation or in case of
spermatidic arrest; and, finally, urofollitropin could be useful
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in idiopathic infertility in normogonadotropic patients. In
conclusion, we performed for the first time a comparative
study on the effects of different preparations of FSH on in
vitro porcine pre-pubertal SC model. In the landscape of a
personalized medicine, this study opens a window on the
different use of the FSH formulations in relation to various
clinical therapeutic targets.
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